BVS
Bioventus Inc. Class A Common Stock
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Best Medical Devices Stocks 2026 →
Bioventus (BVS) Stock: Buy, Sell, or Hold?
$10.99
-0.19 (-1.70%)
▼
5d:
-3.77%
30d:
-18.95%
90d:
-20.88%
QUANTITATIVE VERDICT
BUY
HIGH Confidence (93%)
Quality Score
59/100
Position
OVERSOLD
30-Day Fair Range
$11.71 – $14.46
Position: OVERSOLD
Forward P/E & Valuation
12.4x
FAIR
vs 11.9x historical avg
Wall Street Target
$16.60
+51.0% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$10.09 / $15.09
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
✅ BUY SIGNAL: BVS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Get Alerted When BVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.81
Based on 9.8% avg growth
INTRINSIC VALUE TODAY
$10.43
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BVS is currently trading at $10.99, which is considered oversold relative to its 30-day fair value range of $11.71 to $14.46. The stock's valuation (Forward PE: 12.4) is in line with its historical norms (11.9). At these levels, the market is pricing in 1.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BVS is in a uptrend. Immediate support is located at $10.09, while resistance sits at $15.09.
Market Sentiment: BVS scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $16.60 (+51.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BVS is in a uptrend. Immediate support is located at $10.09, while resistance sits at $15.09.
Market Sentiment: BVS scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $16.60 (+51.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.71 -
$14.46
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
93.1%
Trading Range & Key Levels
30-Day Trading Range
$11.71 -
$14.46
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.81
(7.4%)
Support Level
$10.09
Resistance Level
$15.09
Current Trend
Uptrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.0% below Wall St target ($16.60)
- NEUTRAL: Market pricing in 1.2% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 75/100 — corrected, stabilizing, and turning up
Fundamental Context
Forward P/E (Next Year Est.)
12.38
Wall Street Target
$16.60
(+51.0%)
Revenue Growth (YoY)
2.7%
Earnings Growth (YoY)
69.7%
Profit Margin
9.8%
Valuation Premium vs History
+1.2% premium
PE vs Historical
12.4 vs 11.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.2%
(market-implied from PE analysis)
1-Year Target
$11.12
(+1%)
2-Year Target
$11.26
(+2%)
3-Year Target
$11.39
(+4%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$10.95
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 15.6%)
$27.26
(+148%)
Base:
(SPY PE: 12.4, Growth: 15.6%)
$16.99
(+55%)
Bear:
(PE: 10.5, Growth: 15.6%)
$14.44
(+31%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 13.80 | Current EPS (TTM): $0.81
Bull Case
$13.48
(+23%)
Analyst growth 9.6%, PE expands to 15.2
Base Case
$12.26
(+12%)
Market implied 9.6%, PE stable at 13.8
Bear Case
$7.60
(-31%)
Severe decline -20.0%, PE contracts to 11.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share BVS Analysis
Share this live BVS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (BVS)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 3, 2026
Daily AI digest
AI Retail Discussion Summary:
Bioventus reported Q3 revenue of $142.4 million, a 3% increase YoY, with Adjusted EBITDA of $28.4 million, up 7% YoY. The company is exploring strategic alternatives to maximize shareholder value.
Key Retail Themes:
earnings report
revenue growth
strategic alternatives
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:29 AM ET
Data refreshes hourly during market hours. Next update: 3:29 AM
Data refreshes hourly during market hours. Next update: 3:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$98 | 52 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
30 analysts |
$340 | 38 SELL |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
30 analysts |
$112 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$119 | 38 SELL |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 39 SELL |
Advanced BVS Option Strategies
Professional options setups generated by AI based on today's BVS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive BVS Research Pages
